Concepedia

Publication | Open Access

Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma

DOIFull Paper Access

245

Citations

26

References

2009

Year

Brad S. Kahl, Nancy L. Bartlett, John P. Leonard, Ling Chen, Kristen N. Ganjoo, Michael E. Williams, Myron S. Czuczman, Katherine Robinson, Robin Joyce, Richard H. van der Jagt,
Cancer

Abstract

Single-agent bendamustine produced a high rate of objective responses with acceptable toxicity in patients with recurrent, rituximab-refractory indolent B-cell lymphoma.

References

YearCitations

Page 1